Resource Summary Report

Generated by ASWG on Jul 30, 2026

BALB/cNj-Foxn1^{nu}/Gpt

RRID:IMSR_GPT:D000521
Type: Organism

Proper Citation

RRID:IMSR_GPT:D000521

Organism Information

URL: https://en.gempharmatech.com/product/details100035_3907479.html

Proper Citation: RRID:IMSR_GPT:D000521

Description: Mus musculus with name BALB/cNj-Foxn1^{nu}/Gpt from IMSR.

Species: Mus musculus

Notes: gene symbol note: forkhead box N1; mutant strain: Foxn1

Affected Gene: forkhead box N1

Catalog Number: GPT:D000521

Database: GemPharmatech

Database Abbreviation: GPT

Availability: embryo

Organism Name: BALB/cNj-Foxn1^{nu}/Gpt

Record Creation Time: 20250513T053918+0000

Record Last Update: 20260725T044608+0000

Ratings and Alerts

No rating or validation information has been found for BALB/cNj-Foxn1^{nu}/Gpt.

No alerts have been found for BALB/cNj-Foxn1^{nu}/Gpt.

Data and Source Information

Source: Integrated Animals

Source Database: GemPharmatech

Usage and Citation Metrics

We found 29 mentions in open access literature.

Listed below are recent publications. The full list is available at ASWG .

Zhang Y, et al. (2026) Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer. Cancer cell, 44(1), 77.

Kong D, et al. (2025) Pp1-87B/PPP1CC-JNK axis integrates apoptosis and ferroptosis-like cell death to regulate cell competition and tumorigenesis. Cell reports, 44(9), 116240.

Han P, et al. (2025) Quercetin-derived microbial metabolite DOPAC potentiates CD8+ T cell anti-tumor immunity via NRF2-mediated mitophagy. Cell metabolism, 37(12), 2438.

He X, et al. (2025) PI3K?? functions as a protein kinase to promote cellular protein O-GlcNAcylation and acetyl-CoA production for tumor growth. Molecular cell, 85(7), 1411.

Gao C, et al. (2025) Hypoxia-induced phase separation of ZHX2 alters chromatin looping to drive cancer metastasis. Molecular cell, 85(8), 1525.

Zhou H, et al. (2025) SEL1L confers reduced EMT and drug resistance to breast cancer cells by promoting Shh degradation. iScience, 28(11), 113876.

Du M, et al. (2025) CircYAP1 inhibits osteosarcoma progression through the miR-135b-5p/FRK axis. iScience, 28(7), 112858.

Song Z, et al. (2025) Mechano-oncogenic cytoskeletal remodeling drives leukemic transformation with mitochondrial vesicle-mediated STING activation. Cell stem cell, 32(4), 581.

Xia T, et al. (2025) DDX5 super-enhancer promotes vasculogenic mimicry formation and metastasis in nasopharyngeal carcinoma by enhancing ADAM10 transcription. Cell reports. Medicine, 6(6), 102146.

Cai G, et al. (2025) UMP functions as an endogenous regulator of NR4A1 to control gastric cancer progression. Molecular cell, 85(23), 4347.

Hu Q, et al. (2025) circATF6 triggers calcium overload to synergize with EGFR-TKI in non-small cell lung cancer via modulation of proteostasis. Cell reports, 44(12), 116659.

Liu S, et al. (2025) The TIM22 carrier translocase supports cell proliferation by facilitating mitochondrial iron uptake for Fe-S biogenesis. Molecular cell, 85(24), 4587.

Wang N, et al. (2025) Pyruvate metabolism enzyme DLAT promotes tumorigenesis by suppressing leucine catabolism. Cell metabolism, 37(6), 1381.

Kwiatkowski N, et al. (2025) CDK2 heterobifunctional degraders co-degrade CDK2 and cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers. Cell chemical biology, 32(4), 556.

Xia Q, et al. (2025) PRMT5-mediated methylation of METTL3 promotes cisplatin resistance in ovarian cancer by facilitating DNA repair mechanisms. Cell reports, 44(4), 115484.

Wang P, et al. (2025) Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312. Cancer research communications, 5(5), 792.

Song W, et al. (2025) Targeting the UFL1-PARP1 axis amplifies anti-tumor immunity. Cell reports, 44(10), 116433.

Ahn DH, et al. (2024) Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(10), 2039.

Wu M, et al. (2024) ZDHHC3-mediated SCAP S-acylation promotes cholesterol biosynthesis and tumor immune escape in hepatocellular carcinoma. Cell reports, 43(11), 114962.

Zhang Q, et al. (2024) Decoding sunitinib resistance in ccRCC: Metabolic-reprogramming-induced ABAT and GABAergic system shifts. iScience, 27(7), 110415.